Type 3 parainfluenza virus (PIV3) causes pneumonia and bronchiolitis in infants and young children throughout the world (3, 7, 21, 25, 36, 37) . PIV3 is second to respiratory syncytial virus (RSV) as the most important viral cause of acute lower respiratory disease requiring hospitalization in infants and young children in the United States (5). Primary infection with PIV3 is associated with serious illness, whereas subsequent infections tend to be less severe (20) . A vaccine is needed to reduce the significant morbidity in infants resulting from primary infection.
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In the past, attempts to produce effective inactivated vaccines against paramyxoviruses have been unsuccessful. For example, a formalin-inactivated PIV3 vaccine failed to induce resistance to disease following natural exposure to the virus (9, 19) . One explanation for this failure may have been the inability of an inactivated vaccine to stimulate local secretory immunoglobulin (Ig) A antibody, which is known to play an important role in restriction of virus replication and illness (6, 8, 12, 14, 22, 28, 41, 45, 47) . Of further concern were the findings that inactivated RSV and measles virus vaccines induced immune responses that resulted in a more severe or an atypical disease following natural infection with the homologous virus (24, 33, 40) . In contrast, live attenuated paramyxovirus vaccines are safe and highly effective for prevention of measles and mumps (4, 38) . Parenteral young infants and failed to confer protection against naturally acquired infection or illness (2) . It is thought that the low levels of maternal antibody in these young infants neutralized the infectivity of the vaccine virus and prevented effective immunization. Importantly, disease potentiation was not observed in these infants. For these reasons, attention has been directed to the development of a live attenuated, intranasally administered PIV3 vaccine for immunoprophylaxis of infants and children (5, 6, 33) .
Two approaches have been taken to develop live attenuated PIV3 vaccines: (i) the production of cold-adapted (ca), temperature-sensitive (ts) mutants of wild-type human PIV3 (1, 17, 18) , and (ii) the use of wild-type bovine parainfluenza virus (a host-range variant) which is closely related antigenically to human PIV3 (5, 16, 33) . Both viruses have been shown to be attenuated in experimental animal hosts, as evidenced by restriction of replication in the lower respiratory tract (5, 16, 18) . Moreover (18) and in the respiratory tract of monkeys immunized with bovine PIV3 vaccine (16, 35) .
In the present study, we evaluated the safety and immunogenicity of the bovine PIV3 vaccine and two passage levels of the ca PIV3 vaccine in adult volunteers. On the first visit, a screening nasal wash specimen was collected from each volunteer and tested for PIV3-specific IgA antibody by kinetic enzyme-linked immunosorbent assay (KELISA) as described below. Only those subjects who had a low level of antibody to PIV3 in their nasal wash specimens were selected for participation in the studies. The good health of the volunteers was confirmed by a normal history, physical examination, complete blood count (including blood urea nitrogen, plasma glucose, and serum alanine aminotransferase), and urinalysis, and by negative tests for human immunodeficiency virus antibody, hepatitis B surface antigen, and pregnancy (females). Those who participated in the studies gave written, informed consent.
All volunteer studies to evaluate the safety, infectivity, and antigenicity of the ca and bovine PIV3 vaccines and to determine the virulence of the wild-type PIV3 strain were conducted in an isolation facility. Briefly, volunteers were admitted to an isolation unit at Francis Scott Key Medical Center or at the Marshall University School of Medicine isolation unit. Volunteers were observed for 3 days before and 10 days after inoculation with vaccine or wild-type virus. Methods for the clinical observations, intranasal administration of virus, and collection of nasal washes for isolating virus have been described elsewhere (11, 13, 29, 30) . Temperatures were taken four times daily, and volunteers were examined twice a day by investigators. A volunteer was considered ill if symptoms or physical findings consistent with parainfluenza illness developed within 10 days after inoculation. The definition of parainfluenza illness was based on any of the following criteria: fever, i.e., an oral temperature .37.70C; systemic illness, i.e., occurrence of myalgia alone or with chills or sweats; upper respiratory tract illness, i.e., the presence of rhinorrhea, pharyngitis, or both on 2 or more consecutive days; and lower respiratory tract illness, i.e., the presence of a persistent cough on 2 or more consecutive days. An illness was attributed to PIV3 when there was laboratory confirmation of PIV3 infection as documented by recovery of virus from nasal washes, development of a fourfold rise in antibody titer, or both.
The safety, infectivity, and antigenicity of the bovine and cpl8 ca PIV3 vaccines were evaluated in a dose-escalating fashion by administering a 106 TCID50 of each vaccine candidate intranasally to volunteers in Baltimore. After demonstrating the safety of these doses of the vaccines, a 10-fold-higher dose of each vaccine was evaluated in another group of subjects. Subsequently, at Marshall University, volunteers were inoculated intranasally with 106.5 TCID50 of cp12 ca PIV3 vaccine to evaluate the safety and infectivity of the lower-passage level of ca virus.
To assess the virulence of the wild-type parent virus of ca PIV3, we administered 106 TCID50 of the JS strain of PIV3 to volunteers intranasally. After this dose failed to cause illness, we gave another group of volunteers a 10-fold-higher dose (107 TCID50) of wild-type PIV3. Since this virus proved to be avirulent, even at the 107 TCID50, we did not pursue additional studies with higher dosages. Immunologic studies. A nasal-wash specimen (10 ml) was collected initially from each volunteer recruited for the studies. IgA antibody to PIV3 in nasal wash specimens was measured by a KELISA described elsewhere (42) . The antigen used in the KELISA was the prototype human strain of PIV3 isolated in 1957 (referred to as PIV3-57). Briefly, the reagents consisted of a purified preparation of PIV3-57 diluted to contain 4 hemagglutinin units of virus which was adsorbed to the plate in carbonate buffer, followed by undiluted nasal wash specimen, rabbit anti-human IgA antibody, goat anti-rabbit antibody conjugated with alkaline phosphatase, and substrate. After the addition of substrate, each well of the 96-well plate was read by using a Vmax kinetic microplate reader (Vmax Molecular Devices, Palo Alto, Calif.). The rate of color development (optical density [OD] milliunits per minute) in each well was calculated as the slope of the regression line defined by the OD readings for that well. We selected the most immunologically susceptible subjects for the study, i.e., those volunteers whose levels of nasal wash IgA PIV3 antibodies were in the lowest quartile of the samples tested.
For determination of antibody responses, serum and nasal wash specimens were collected before vaccination or challenge and 4 weeks afterwards. The methods for collecting, pooling, and concentrating the nasal wash specimens were described elsewhere (30, 34) . Serum samples were assayed for antibodies to PIV3 by hemagglutination inhibition assay (HAI) at 25°C by using 0.5% guinea pig erythrocytes and, as antigen, human wild-type PIV3-57. The antibody titer was defined as the endpoint serum dilution that inhibited hemagglutination.
A previously described ELISA (31, 32) was used to measure serum IgG and nasal wash IgA antibodies. The antigen used in the ELISA was the purified human PIV3-57 described above. The sequence of reagents from solid phase outward consisted of the following: (i) PIV3-57; (ii) serum (initial dilution, 1:40) or nasal wash (initial dilution, 1:2) specimen; (iii) rabbit anti-human IgG or IgA; (iv) goat anti-rabbit IgG conjugated with alkaline phosphatase; and (v) p-nitrophenyl phosphate disodium substrate. The ELISA titer was expressed as the highest dilution in which the OD of the antigen-containing well was at least 0.2 OD units and greater than twice the OD of the respective control well lacking antigen. The ELISA nasal wash anti-PIV3 IgA titers were corrected to a total concentration of 100 mg/ml.
Isolation and quantitation of virus. In studies with volunteers and chimpanzees, 0. Phenotypic characterization of isolates from chimpanzees. Tissue-passage isolates from nasopharyngeal washes and tracheal lavage washes were first characterized for the temperature-sensitive (ts) property by plaque assay in L-132 cells at 32 and 39°C. Briefly, monolayers of L-132 cells were inoculated with serial 10-fold dilutions of an isolate which was allowed to adsorb at room temperature for 90 min and overlaid with L-15 containing 10% agamma calf serum and 0.9% methyl cellulose. Plates were fixed in formalin and stained with hematoxylin and eosin after 5 days of incubation at 25°C or after 3 days of incubation at 32 or 39°C.
As shown previously (1) The vaccine virus also induced a high level (1:128) of HAI the upper and lower respiratory tracts of the chimpanzees antibody in the serum samples of the chimpanzees.
infected with cp12 ca PIV3 were evaluated for the ts and ca Infection with cpl2 ca PIV3 induced resistance against phenotypes to determine the stability of these properties challenge with wild-type virus ( Table 3 ). The replication of following replication in vivo. Chimpanzees 1406 and 1417 the JS wild-type challenge virus was almost completely each shed a mixture of attenuated viruses (Table 4) . Chimrestricted in the upper and lower respiratory tracts of anipanzee 1406 shed virus that was identical to the vaccine mals previously immunized with live attenuated cpl2 ca virus in ts and ca phenotypes on day 5 (nasopharyngeal PIV3 or infected with wild-type PIV3. Thus, prior infection sample) and on day 4 (tracheal lavage sample). The virus with the cpl2 ca PIV3 induced a high level of resistance to a isolated from the nasopharyngeal washes on days 1, 4, 7, 8, virulent wild-type PIV3 which is capable of replicating to and 9 postinoculation and from the tracheal lavage specihigh titer in the respiratory tract of susceptible chimpanzees. mens on days 6 and 10 had lost the ts phenotype. Seven of The genetic stability of the ca PIV3 isolated from chimthe isolates did retain the ca phenotype (Table 4) . Virus panzees was then examined. Viral isolates recovered from recovered from chimpanzee 1417 had lost the ts phenotype (1, 5, 33) . Human and bovine PIV3 are closely related antigenically and share several neutralization epitopes on the F and HN glycoproteins, each of which are major protective antigens (10, 15, 26, 27, 39) . The bovine PIV3 was previously shown to be attenuated in rhesus monkeys and chimpanzees (16) and able to induce significant resistance to human wild-type PIV3, as documented by a reduction in virus replication in challenged cotton rats or squirrel monkeys (15, 16) . Three different cold-passage levels of ca PIV3 which possess attenuation, ts, and ca phenotypes have been studied in hamsters (1, 17) . The attenuation phenotype was manifest by restriction of virus replication in weanling hamsters (17) . Also, the PIV3 ca mutants have induced resistance to challenge with wild-type PIV3 in immunized hamsters (18 (6) . Our findings from studies in fully susceptible (seronegative) chimpanzees indicated that, compared with the wild-type JS parent PIV3, cpl2 ca PIV3 was equally restricted in replication in the upper and lower respiratory tracts (35) . This suggests that one or more mutations, in addition to those responsible for the ts phenotype, contribute to the restriction of replication of the cpl2 PIV3 in the chimpanzee. It is possible that the mutations that confer the attenuation phenotype differ from those that confer the ts phenotype, but this remains to be established. Infection of the chimpanzee with the cpl2 ca PIV3 induced a high level of resistance to challenge with wild-type JS strain PIV3, indicating that, despite the restricted level of replication of the cpl2 ca PIV3, virus replication was sufficient to induce a high level of resistance to wild-type virus (35) .
The cpl2 PIV3 generally lost the ts phenotype after replication in chimpanzees, whereas all but two of the isolates that were tested retained the ca phenotype. The loss of the ts phenotype would suggest that the cpl2 virus resembles several of the influenza A and RSV ts vaccines previously studied (6, 43, 44) and that the cpl2 is not an acceptable candidate vaccine for use in human beings. It is hoped that the more extensively passaged cpl8 and cp45 viruses are more stable after replication in the fully susceptible host.
It is encouraging that the ca mutant (cpl2) that was least attenuated in hamsters appears to be satisfactorily attenuated and immunogenic for chimpanzees. Equally encouraging was the high level of resistance to wild-type virus challenge induced by the cpl2 ca PIV3. Because the cpl8 and cp45 viruses are more restricted than the cpl2 virus in hamsters, it is anticipated that they will be even more attenuated for humans and possibly will be more genetically stable than cpl2. To determine whether the ca and bovine PIV3s will be satisfactorily attenuated and sufficiently immunogenic for use as vaccine candidates, both strains are being evaluated in young children and infants. Because of the inability to predict the level of attenuation of these viruses for susceptible young children, these vaccine candidates will be evaluated cautiously in seropositive young children first and then, if they prove to be safe, in seronegative, fully susceptible children and infants. These studies will determine which PIV3 vaccine candidate is most acceptable, in terms of level of attenuation and immunogenicity, for immunoprophylaxis of fully susceptible infants and children.
